Long-term pioglitazone treatment augments insulin sensitivity and PKCε and PKC-θ activation in skeletal muscles in sucrose fed rats

Physiological Research

Volumn 59, Issue 4, 2010, Pages 509-516

  Markova I ^a   Zidek V ^b   Musilova A ^b   Simakova M ^b   Mlejnek, P ^b   Kazdova L ^a   Pravenec, M ^b  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^b INSTITUTE OF PHYSIOLOGY   (Czech Republic)

Author keywords

Insulin resistance; Muscle lipids; Novel PKC; Pioglitazone; Rat

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; CD36 ANTIGEN; GLYCOGEN; INSULIN; ISOENZYME; PIOGLITAZONE; PKCQ PROTEIN, RAT; PRKCE PROTEIN, RAT; PROTEIN KINASE C; PROTEIN KINASE C EPSILON; TRIACYLGLYCEROL;

ANIMAL; ARTICLE; CONGENIC STRAIN; DISEASE MODEL; DRUG EFFECT; ENZYMOLOGY; GENETICS; GLUCOSE BLOOD LEVEL; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; METABOLISM; PATHOPHYSIOLOGY; PROTEIN TRANSPORT; RAT; SKELETAL MUSCLE; SPONTANEOUSLY HYPERTENSIVE RAT; SUGAR INTAKE; TIME;

ANIMALS; ANIMALS, CONGENIC; ANTIGENS, CD36; BLOOD GLUCOSE; DIETARY SUCROSE; DISEASE MODELS, ANIMAL; GLYCOGEN; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; ISOENZYMES; MALE; METABOLIC SYNDROME X; MUSCLE, SKELETAL; PROTEIN KINASE C; PROTEIN KINASE C-EPSILON; PROTEIN TRANSPORT; RATS; RATS, INBRED SHR; THIAZOLIDINEDIONES; TIME FACTORS; TRIGLYCERIDES;

EID: 77958121934     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. DIVIŠOVÁ J, KAZDOVÁ L, HUBOVÁ M, MESCHISVILI E: Relationship between insulin resistance and muscle triglyceride content in nonobese and obese experimental models of insulin resistance syndrome. Ann N Y Acad Sci 967: 440-445, 2002.
2. FOROUHI NG, JENKINSON G, THOMAS EL, MULLICK S, MIERISOVA S, BHONSLE U, MCKEIGUE PM, BELL JD: Relation of triglyceride stores in skeletal muscle cells to central obesity and insulin sensitivity in European and South Asian men. Diabetologia 42: 932-935, 1999.
3. GAO Z, WANG Z, ZHANG X, BUTLER AA, ZUBERI A, GAWRONSKA-KOZAK B, LEFEVRE M, YORK D, RAVUSSIN E, BERTHOUD HR, MCGUINNESS O, CEFALU WT, YE J: Inactivation of PKC-θ leads to increased susceptibility to obesity and dietary insulin resistance in mice. Am J Physiol 292: E84-E91, 2007.
4. HAEMMERLE G, ZIMMERMANN R, HAYN M, THEUSSL C, WAEG G, WAGNER E, SATTLER W, MAGIN TM, WAGNER EF, ZECHNER R: Hormone-sensitive lipase deficiency in mice causes diglyceride accumulation in adipose tissue, muscle, and testis. J Biol Chem 277: 4806-4815, 2002.
5. HOCKINGS PD, CHANGANI KK, SAEED N, REID DG, BIRMINGHAM J, O'BRIEN P, OSBORNE J, TOSELAND CN, BUCKINGHAM RE: Rapid reversal of hepatic steatosis, and reduction of muscle triglyceride, by rosiglitazone: MRI/S studies in Zucker fatty rats. Diabetes Obes Metab 5: 234-243, 2003.
6. JUCKER BM, SCHAEFFER TR, HAIMBACH RE, MAYER ME, OHLSTEIN DH, SMITH SA, COBITZ AR, SARKAR SK: Reduction of intramyocellular lipid following short-term rosiglitazone treatment in Zucker fatty rats: an in vivo nuclear magnetic resonance study. Metabolism 52: 218-225, 2003.
7. KELLEY DE, GOODPASTER BH, STORLIEN L: Muscle triglyceride and insulin resistance. Annu Rev Nutr 22: 325-346, 2002.
8. KIM JK, FILLMORE JJ, GAVRILOVA O, CHAO L, HIGASHIMORI T, CHOI H, KIM HJ, YU C, CHEN Y, QU X: Differential effects of rosiglitazone on skeletal muscle and liver insulin resistance in A-ZIP/F-1 fatless mice. Diabetes 52: 1311-1318, 2003.
9. KOH EH, KIM MS, PARK JY, KIM HS, YOUN JY, PARK HS, YOUN JH, LEE KU: Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation. Diabetes 52: 2331-2337, 2003.
10. 1H-spectroscopic study in Zucker diabetic fatty rats. Diabetes 52: 138-144, 2003.
11. LESSARD SJ, LO GIUDICE SL, LAU W, REID JJ, TURNER N, FEBBRAIO MA, HAWLEY JA, WATT MJ: Rosiglitazone enhances glucose tolerance by mechanisms other than reduction of fatty acid accumulation within skeletal muscle. Endocrinology 145: 5665-5670, 2004.
12. NECKÁŘ J, MARKOVÁ I, NOVÁK F, NOVÁKOVÁ O, SZÁRSZOI O, OŠŤÁDAL B, KOLÁŘ F: Increased expression and altered subcellular distribution of PKC-delta in chronically hypoxic rat myocardium: involvement in cardioprotection. Am J Physiol 288: H1566-H1572, 2005.
13. PERSEGHIN G, SCIFO P, DE COBELLI F, PAGLIATO E, BATTEZZATI A, ARCELLONI C, VANZULLI A, TESTOLIN G, POZZA G, DEL MASCHIO A, LUZI L: Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans. Diabetes 48: 1600-1606, 1999.
14. PHILLIPS DIW, CADDY S, ILIC V, FIELDING BA, FRAYN KN, BORTHWICK AC, TAYLOR R: Intramyocellular triglyceride and muscle insulin sensitivity: evidence for a relationship in nondiabetic subjects. Metabolism 45: 947-950, 1996.
15. PRAVENEC M, ZÍDEK V, ŠIMÁKOVÁ M, KŘEN V, KŘENOVÁ D, HORKÝ K, JÁCHYMOVÁ M, MÍKOVÁ B, KAZDOVÁ L, AITMAN TJ: Genetics of Cd36 and the clustering of multiple cardiovascular risk factors in spontaneous hypertension. J Clin Invest 103: 1651-1657, 1999.
16. PRAVENEC M, KAZDOVÁ L, LANDA V, ZÍDEK V, MLEJNEK P, JANSA P, WANG J, QI N, KURTZ TW: Transgenic and recombinant resistin impair skeletal muscle glucose metabolism in the spontaneously hypertensive rat. J Biol Chem 278: 45209-45215, 2003.
17. QI N, KAZDOVÁ L, ZÍDEK V, LANDA V, KŘEN V, PERSHADSINGH HA, LEZIN ES, ABUMRAD NA, PRAVENEC M, KURTZ TW: Pharmacogenetic evidence that Cd36 is a key determinant of the metabolic effects of pioglitazone. J Biol Chem 277: 48501-48507, 2002.
18. QI NR, WANG J, ZÍDEK V, LANDA V, MLEJNEK P, KAZDOVÁ L, PRAVENEC M, KURTZ TW: A new transgenic rat model of hepatic steatosis and the metabolic syndrome. Hypertension 45: 1004-1011, 2005.
19. RASOULI N, RAUE U, MILES LM, LU T, DI GREGORIO GB, ELBEIN SC, KERN PA: Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue. Am J Physiol 288: E930-E934, 2005.
20. SCHMITZ-PEIFFER C, BROWNE CL, OAKES ND, WATKINSON A, CHISHOLM DJ, KRAEGEN EW, BIDEN TJ: Alterations in the expression and cellular localization of protein kinase C isozymes ε and θ are associated with insulin resistance in skeletal muscle of the high-fat-fed rat. Diabetes 46: 169-178, 1997.
21. SCHMITZ-PEIFFER C, OAKES ND, BROWNE CL, KRAEGEN EW, BIDEN TJ: Reversal of chronic alterations of skeletal muscle protein kinase C from fat-fed rats by BRL-49653. Am J Physiol 273: E915-E921, 1997.
22. SCHMITZ-PEIFFER C: Protein kinase C and lipid-induced insulin resistance in skeletal muscle. Ann N Y Acad Sci 967: 146-157, 2002.
23. SCHMITZ-PEIFFER C, LAYBUTT DR, BURCHFIELD JG, GURISIK E, NARASIMHAN S, MITCHELL CJ, PEDERSEN DJ, BRAUN U, COONEY GJ, LEITGES M, BIDEN TJ: Inhibition of PKC epsilon improves glucose-stimulated insulin secretion and reduces insulin clearance. Cell Metab 6: 320-328, 2007.
24. SCHMITZ-PEIFFER C, BIDEN TJ: Protein kinase C function in muscle, liver, and beta-cells and its therapeutic implications for type 2 diabetes. Diabetes 57: 1774-1783, 2008.
25. SERRA C, FEDERICI M, BUONGIORNO A, SENNI MI, MORELLI S, SEGRATELLA E, PASCUCCIO M, TIVERON C, MATTEI E, TATANGELO L, LAURO R, MOLINARO M, GIACCARI A, BOUCHÉ M: Transgenic mice with dominant negative PKC-θ in skeletal muscle: a new model of insulin resistance and obesity. J Cell Physiol 196: 89-97, 2003.
26. YU C, CHEN Y, ZONG H, ZHANG D, ZONG H, WANG Y, BERGERON R, KIM JK, CUSHMAN SW, COONEY GJ, ATCHESON B, WHITE MF, KRAEGEN EW, SHULMAN GI: Mechanism by which fatty acids inhibit insulin activation of IRS-1 associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem 277: 50230-50236, 2002.
27. ZINN A, FELSON S, FISHER E, SCHWARTZBARD A: Reassessing the cardiovascular risks and benefits of thiazolidinediones. Clin Cardiol 31: 397-403, 2008.